Public Policy Resources

The American Cancer Society Cancer Action Network (ACS CAN) urges Congress to increase funding for the Centers for Disease Control and Prevention’s (CDC) cancer programs to at least $482.9 million in Fiscal Year 2027.

The American Cancer Society Cancer Action Network (ACS CAN) calls on Congress to fund the Centers for Disease Control and Prevention’s (CDC) National Program for Cancer Registries (NPCR) at $63.4 million in FY 2027. Established by Congress in 1992, the National Program for Cancer Registries suppo

In a letter to Interview magazine Editor and Chief Mel Ottenberg, the American Cancer Society Cancer Action Network (ACS CAN), alongside the American Heart Association, American Lung Association, Campaign for Tobacco-Free Kids, Truth Initiative, and Vital Strategies, expressed strong dis

In a letter to Vanity Fair Global Editorial Director Mark Guiducci, the American Cancer Society Cancer Action Network (ACS CAN), alongside the American Heart Association, American Lung Association, Campaign for Tobacco-Free Kids, Truth Initiative, and Vital Strategies, expressed strong disappoint

The American Cancer Society Cancer Action Network (ACS CAN) calls on Congress to fund the Centers for Disease Control and Prevention’s (CDC) National Breast and Cervical Cancer Early Detection Program (NBCCEDP) at $265 million in FY 2027 and to pass the Screening for Communities to Receive Early

The American Cancer Society Cancer Action Network (ACS CAN) calls on Congress to fund the Centers for Disease Control and Prevention’s (CDC) lifesaving Colorectal Cancer Control Program (CRCCP) at $51 million in FY 2027.

The American Cancer Society Cancer Action Network (ACS CAN) calls on Congress to support a sustained funding level of $310 million in Fiscal Year 2027 for fact based tobacco prevention and cessation programs and ensure the funding is used as Congress intended.

Pharmacists are playing an increasingly important public health role, in part due to the widespread presence of pharmacies in communities, with nearly 89% of people in the U.S.

In March 2026, FDA released the “Flavored Electronic Nicotine Delivery Systems (ENDS) Premarket Applications – Considerations Related to Youth Risk; Draft Guidance for Industry." Draft Guidance provides FDA's current thinking about the topic of the guidance. The undersigned public health, medical, civil righs and community organizations conclude that the Draft Guidance fails to recognize the well-established history of signficant variations in youth flavor preferences over time, often caused by regulatory decisions, and this fundamental flaw threatens to open the regulatory door to a wide array of FDA-authorized products that would appeal and be accessible to youth, without signficant countervailing health benefits to adults who smoke.